S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

$2.88
+0.14 (+5.11%)
(As of 03/27/2024 ET)
Today's Range
$2.72
$2.95
50-Day Range
$2.71
$19.57
52-Week Range
$2.67
$31.77
Volume
3.24 million shs
Average Volume
2.99 million shs
Market Capitalization
$195.21 million
P/E Ratio
4.11
Dividend Yield
N/A
Price Target
$38.33

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,231.0% Upside
$38.33 Price Target
Short Interest
Bearish
10.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.02mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$378,754 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.48) to ($0.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

162nd out of 938 stocks

Biotechnology Industry

4th out of 26 stocks

AMLX stock logo

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Stock Price History

AMLX Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
384
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.33
High Stock Price Target
$48.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+1,231.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$49.27 million
Pretax Margin
14.26%

Debt

Sales & Book Value

Annual Sales
$380.79 million
Cash Flow
$0.64 per share
Book Value
$6.42 per share

Miscellaneous

Free Float
59,784,000
Market Cap
$195.21 million
Optionable
Optionable
Beta
-0.66
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 33)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 53)
    Chief Legal Officer & General Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Linda A. Arsenault
    Chief Human Resources Officer
  • Mr. Chris Aiello
    Head of Canada & GM
  • Mr. Keith White
    Head of Global Market Access

AMLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 1 year price objectives for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $27.00 to $48.00. On average, they expect the company's share price to reach $38.33 in the next twelve months. This suggests a possible upside of 1,231.0% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2024?

Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of 2024. Since then, AMLX shares have decreased by 80.4% and is now trading at $2.88.
View the best growth stocks for 2024 here
.

Are investors shorting Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 5,090,000 shares, an increase of 16.5% from the February 29th total of 4,370,000 shares. Based on an average trading volume of 2,790,000 shares, the short-interest ratio is currently 1.8 days. Approximately 10.7% of the shares of the company are short sold.
View Amylyx Pharmaceuticals' Short Interest
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The firm had revenue of $108.45 million for the quarter, compared to analysts' expectations of $106.40 million. Amylyx Pharmaceuticals had a trailing twelve-month return on equity of 12.39% and a net margin of 12.94%. During the same period in the previous year, the company posted ($0.65) EPS.

When did Amylyx Pharmaceuticals IPO?

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.81%), Vanguard Group Inc. (7.78%), Point72 Asset Management L.P. (4.07%), Stonepine Capital Management LLC (3.70%), Perceptive Advisors LLC (2.76%) and Franklin Resources Inc. (1.96%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends
.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMLX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners